ASMB

Assembly Biosciences, Inc. · NASDAQ · Healthcare · USD · 10-K for 2025, filed 2026-03-19

Figures on this page computed 2026-11-08 12:40 UTC

Last close

20.00USD

Market data, 2026-11-05

Except where said otherwise: 10-K for 2025, filed 2026-03-19

n/aP/E
We do not hold this figure for this company, so there is nothing to place.
Price / Earnings per Share (diluted)
Source
computed
Fiscal year
2025
Accession
0001193125-26-115992
Reported in
USD
- computed
- 10-K for 2025, filed 2026-03-19
The filing itself
n/aROIC
We do not hold this figure for this company, so there is nothing to place.
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
Source
computed
Fiscal year
2025
Accession
0001193125-26-115992
Reported in
USD
- 10-K for 2025, filed 2026-03-19
- 10-K for 2025, filed 2026-03-19
- 10-K for 2025, filed 2026-03-19
- 10-Q for 2025, filed 2026-08-13
- 10-K for 2025, filed 2026-03-19
- 10-Q for 2025, filed 2026-08-13
The filing itself
-8.5%Net margin
Net Income / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001193125-26-115992
Reported in
USD
- 10-K for 2025, filed 2026-03-19
- 10-K for 2025, filed 2026-03-19
The filing itself
-56.9%FCF margin
Free Cash Flow / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001193125-26-115992
Reported in
USD
- 10-K for 2025, filed 2026-03-19
- 10-K for 2025, filed 2026-03-19
The filing itself
n/aDebt/equity
We do not hold this figure for this company, so there is nothing to place.
Total Debt / Shareholders' Equity
Source
computed
Fiscal year
2025
Accession
0001193125-26-115992
Reported in
USD
- 10-K for 2025, filed 2026-03-19
- 10-Q for 2025, filed 2026-08-13
The filing itself
n/aDividend yield
We do not hold this figure for this company, so there is nothing to place.
Source
computed
Taken on
2026-11-07
Reported in
USD
- computed

Growth is the furthest below its sector's middle: 0.48 against 0.50 on the market's range.

What it pays out: n/aWe do not hold this figure for this company, so there is nothing to place.

Five bars, one line

lens 7 of 9

3.10x

0.09x

0.82x

n/a

0.15x

SalesProfitFree cash flowDebtPrice

Each bar against this company's own average; the line is that average.

Filed2025

Market data2026-11-05

Each against its own average

4 of 5 read

Except where said otherwise: 10-K for 2025, filed 2026-03-19

Sales3.10x
Its own average over 10 years, 23.3M.
Profit0.09x
Its own average over 10 years, -66.8M.
Free cash flow0.82x
Its own average over 10 years, -49.9M.
Debtn/a
Its own average over 2 years, 1.2M.
Price0.15x
Its own average over 11 years, 136. Market data, 2026-11-05

Sales is furthest from its own average, at 3.10 times.

Sales is 3.10 times its own 10-year average; Profit is 0.09 times its own 10-year average; Free cash flow is 0.82 times its own 10-year average; Price is 0.15 times its own 11-year average.

Every figure in this lens

Except where said otherwise: 10-K for 2025, filed 2026-03-19

Sales against its own 10-year average3.10
Source
filed
Statement
income
Fiscal year
2025
Accession
0001193125-26-115992
Reported in
USD
The filing itself
Profit against its own 10-year average0.09
Source
filed
Statement
income
Fiscal year
2025
Accession
0001193125-26-115992
Reported in
USD
The filing itself
Free cash flow against its own 10-year average0.82
Source
filed
Statement
income
Fiscal year
2025
Accession
0001193125-26-115992
Reported in
USD
The filing itself
Debt against its own 2-year averagen/a
Not held.
Source
filed
Statement
income
Fiscal year
2025
Accession
0001193125-26-115992
Reported in
USD
The filing itself
Price against its own 11-year average0.15Market data, 2026-11-05
Source
market
Taken on
2026-11-05
Reported in
USD